JNJ vs DGX
By Alex · Tickerpine
Johnson & Johnson vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DGX |
|---|---|---|
| Price | $254.66 | $209.88 |
| Market cap | $613.02B | $23.23B |
| P/E ratio | 29.5 | 23.2 |
| ROE | 26.42% | 14.54% |
| Profit margin | 21.83% | 9.08% |
| Revenue growth | 9.90% | 9.20% |
| Dividend yield | 2.10% | 1.64% |
| Beta | 0.26 | 0.59 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DGX in plain English
- JNJ is the bigger company — about 26.4× the market cap of DGX.
- DGX is cheaper on earnings (P/E 23.2 vs 29.5).
- JNJ earns a higher return on equity (26% vs 15%).
- JNJ is growing revenue faster (10% vs 9%).
- JNJ has the higher dividend yield (2.10% vs 1.64%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.